@article{fdi:010053071,
  title = {{I}n vitro activity of nicotinamide/antileishmanial drug combinations},
  author = {{G}azanion, {E}lodie and {V}ergnes, {B}aptiste and {S}eveno, {M}arie and {G}arcia, {D}eborah and {O}ury, {B}runo and {A}it-{O}udhia, {K}. and {O}uaissi, {A}. and {S}ereno, {D}enis},
  abstract = {{T}o improve the management of leishmaniasis, new drugs and/or alternative therapeutic strategies are required. {C}ombination therapy of antileishmanial drugs is currently considered as one of the most rational approaches to lower treatment failure rate and limit drug resistance spreading. {N}icotinamide ({NA}m), also known as vitamin {B}3 that is already is used in human therapy, exerts in vitro antileishmanial activity. {D}rug combination studies, performed on {L}. infantum axenic amastigotes, revealed that {NA}m significantly improves the antileishmanial activity of trivalent antimony in a synergistic manner while it shows additive activity with amphotericin {B} and slightly antagonizes pentamidine activity. {NA}m also significantly increases the toxicity of pentavalent antimony against the intracellular forms of {L} infantum, {L} amazonensis and {L}. braziliensis. {T}he potential of {NA}m to be used as adjuvant during leishmaniasis chemotherapy is further discussed.},
  keywords = {{N}icotinamide ; {A}ntimonials ; {L}eishmania ; {D}rug combinations},
  journal = {{P}arasitology {I}nternational},
  volume = {60},
  numero = {1},
  pages = {19--24},
  ISSN = {1383-5769},
  year = {2011},
  DOI = {10.1016/j.parint.2010.09.005},
  URL = {http://www.documentation.ird.fr/hor/fdi:010053071},
}